Albany Molecular Research Inc. (NASDAQ:AMRI)’s share price was down 5.2% during mid-day trading on Monday . The stock traded as low as $13.52 and last traded at $13.58, with a volume of 194,195 shares changing hands. The stock had previously closed at $14.33.

Separately, Morgan Stanley reiterated a “buy” rating on shares of Albany Molecular Research in a research report on Sunday, May 8th.

The company’s market cap is $476.16 million. The stock has a 50-day moving average price of $14.09 and a 200 day moving average price of $14.98.

Albany Molecular Research (NASDAQ:AMRI) last posted its earnings results on Tuesday, May 10th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $102.80 million for the quarter, compared to analysts’ expectations of $107.20 million. On average, equities analysts anticipate that Albany Molecular Research Inc. will post $1.04 earnings per share for the current fiscal year.

In other Albany Molecular Research news, Director Kevin Oconnor sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total transaction of $72,050.00. Following the sale, the director now owns 52,955 shares of the company’s stock, valued at $763,081.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO George Svokos bought 12,500 shares of the firm’s stock in a transaction on Friday, May 13th. The shares were bought at an average cost of $12.82 per share, for a total transaction of $160,250.00. Following the purchase, the chief operating officer now owns 108,685 shares of the company’s stock, valued at approximately $1,393,341.70. The disclosure for this purchase can be found here.

Several institutional investors have modified their holdings of AMRI. Philadelphia Trust Co. raised its position in shares of Albany Molecular Research by 10.9% in the fourth quarter. Philadelphia Trust Co. now owns 153,475 shares of the company’s stock worth $3,056,000 after buying an additional 15,025 shares during the period. Mutual of America Capital Management LLC raised its position in shares of Albany Molecular Research by 5.8% in the fourth quarter. Mutual of America Capital Management LLC now owns 158,399 shares of the company’s stock worth $3,144,000 after buying an additional 8,689 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Albany Molecular Research by 5.8% in the fourth quarter. Bank of Montreal Can now owns 878,664 shares of the company’s stock worth $17,442,000 after buying an additional 48,436 shares during the period.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.